Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3838835

CCCCCCCC(CC)c1ccccc1S.Cl

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PPARG known ✓ P37231 2/20 0.35
NR1I2 O75469 1/20 0.42
CYSLTR2 Q9NS75 2/20 0.41
CYSLTR1 Q9Y271 2/20 0.41
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
CSNK1E P49674 1/20 0.36
ALDH1A1 P00352 1/20 0.33
SLC2A1 P11166 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9188305 0.98 NR1I2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL11560383 0.86 CYSLTR2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL8524531 0.85 NR1I2 (0.45) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL15105217 0.83 TSHR (0.36) CYSLTR2CYSLTR1
SCHEMBL9797000 0.81 NR1I2 (0.46) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL11625320 0.81 NR1I2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL9136134 0.81 NR1I2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL9141696 0.81 NR1I2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL9138492 0.81 NR1I2 (0.43) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2
SCHEMBL9632149 0.81 NR1I2 (0.46) NR1I2CYSLTR2CYSLTR1PRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682609-B1 METHOD OF MODIFYING A FLUOROPOLYMER AND ARTICLES THEREBY 3M INNOVATIVE PROPERTIES CO (US) 2015-03-11 EP disclosed
EP-2014703-B1 Process of preparing a composite article 3M INNOVATIVE PROPERTIES CO (US) 2009-12-09 EP disclosed
EP-2014703-A1 Method of modifying a fluoropolymer and articles thereby 3M Innovative Properties Company (US) 2009-01-14 EP disclosed
EP-1453896-B1 PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M INNOVATIVE PROPERTIES CO (US) 2008-04-09 EP disclosed
EP-1461376-B1 IMPROVED PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M INNOVATIVE PROPERTIES CO (US) 2006-12-20 EP disclosed
US-7140413-B2 Method of modifying a fluoropolymer and articles thereby 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-11-28 US disclosed
EP-1682609-A1 METHOD OF MODIFYING A FLUOROPOLYMER AND ARTICLES THEREBY 3M Innovative Properties Company (US) 2006-07-26 EP disclosed
US-20060029812-A1 Method of modifying a fluoropolymer and articles thereby 3M INNOVATIVE PROPERTIES COMPANY 2006-02-09 US disclosed
US-6986947-B2 Method of modifying a fluoropolymer and articles thereby 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-01-17 US disclosed
WO-2005037902-A1 METHOD OF MODIFYING A FLUOROPOLYMER AND ARTICLES THEREBY 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-28 WO disclosed
US-20050080212-A1 Method of modifying a fluoropolymer and articles thereby 3M INNOVATIVE PROPERTIES COMPANY 2005-04-14 US disclosed
US-6844030-B2 Process for modifying a polymeric surface 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-01-18 US disclosed
EP-1461376-A1 IMPROVED PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M Innovative Properties Company (US) 2004-09-29 EP disclosed
EP-1453896-A1 PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M Innovative Properties Company (US) 2004-09-08 EP disclosed
US-6752894-B2 EXPOSURE TO ACTINIC RADIATION; DISCOLORATION INHIBITION; OXIDATION RESISTANCE 3M INNOVATIVE PROPERTIES COMPANY 2004-06-22 US disclosed
US-20030159915-A1 Process for modifying a polymeric surface 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
US-20030162022-A1 Process for modifying a polymeric surface 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003051965-A1 PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-26 WO disclosed
WO-2003051966-A1 IMPROVED PROCESS FOR MODIFYING A POLYMERIC SURFACE 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030159915-A1 Process for modifying a polymeric surface FSCN1, FLNA, FLNB PPARG 4055/4885NR1I2 4711/4885CYSLTR2 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.